Sierra Oncology

News

GSK gets June 2023 FDA decision date for momelotinib

The clock is now ticking on the FDA's review of GSK's momelotinib for myelofibrosis patients with anaemia – the centrepiece of its $1.9 billion

News

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.<

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks